Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery

• Main Authors: Yuxin Chen (Author), Lulu Han (Author), Xiaoyan Qiu (Author), Meng Wang (Author), Zheng Chen (Author), Ying Cai (Author), Yong Xin (Author), Yanfang Lv (Author), Ankang Hu (Author), Dafei Chai (Author), Liantao Li (Author), Huizhong Li (Author), Junnian Zheng (Author), Gang Wang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Albumin-bound paclitaxel (abPTX) has been widely used in cancer treatment. However, dose-related side effects, such as myelosuppression, restrict its clinical application. Cell-based targeting drug delivery is a promising way to mitigate systematic side-effects and improve antitumoral efficacy. In t...